Skip to main content
. 2020 Jul 15;64(4):149–156. doi: 10.3345/cep.2020.00871

Fig. 5.

Fig. 5.

Enhanced activity of the RAS-MAPK signaling pathway due to the loss-of-function mutation of the NF1 gene and mode of selumetinib action. MAPK, mitogen-activated protein kinase; ERK, extracellular-signal-regulated kinase.